scholarly journals Glioma with Leptomeningeal Spread Mimics Chronic Meningoencephalitis in a Young Adult

2021 ◽  
pp. 179-183
Author(s):  
Ann-Kristin Becker ◽  
Marta Leonora Frank ◽  
Michael Friese ◽  
Joachim Röther
Keyword(s):  
Brain Tumor ◽  
Back Pain ◽  
Young Adult ◽  
Lower Back Pain ◽  
Low Grade Glioma ◽  
Low Grade ◽  
Who Grade ◽  
Leptomeningeal Spread ◽  
Lower Back ◽  
Uncommon Case

The most malignant type of intrinsic brain tumor is glioblastoma (WHO grade IV). Primary leptomeningeal spread is rare and leads to a variety of differential considerations, as there is no typical clinical or imaging pattern. Here we present a rare and uncommon case of a primary leptomeningeal glioblastoma in combination with a low-grade glioma in a 21-year-old male, initially presenting with only headache and lower back pain. The presented case illustrates the challenging differential considerations and the severe course of leptomeningeal glioblastomas.

scholarly journals Spinal Intradural, Extramedullary Ependymoma with Astrocytoma Component: A Case Report and Review of the Literature

2016 ◽  
Vol 2016 ◽  
pp. 1-5 ◽  
Author(s):  
Gene M. Weinstein ◽  
Knarik Arkun ◽  
James Kryzanski ◽  
Michael Lanfranchi ◽  
Gaurav K. Gupta ◽  
...  
Keyword(s):  
Back Pain ◽  
Case Report ◽  
Lower Back Pain ◽  
Low Grade ◽  
Review Of The Literature ◽  
Pathologic Evaluation ◽  
Lower Back ◽  
Spinal Lesions ◽  
First Case ◽  
Intradural Extramedullary

Ependymomas are common spinal lesions, with the vast majority arising in an intramedullary location. Several cases have been described in the literature of ependymomas in an intradural, extramedullary location. The authors present a case of a 56-year-old female who presented with several weeks of lower back pain and weakness. MRI revealed an intradural, extramedullary enhancing mass at L1-L2. The mass was successfully resected surgically. Pathologic evaluation revealed a low grade glioma with components of both ependymoma and pilocytic astrocytoma with MUTYH G382D mutation. Extramedullary ependymomas are very rare tumors. To the authors’ knowledge, this is the first case of ependymoma/astrocytoma collision tumors described in an extramedullary location.

Chronic lower back pain in a young adult

2016 ◽  
Vol 19 (9) ◽  
pp. 929-931
Author(s):  
Adam Austin ◽  
Patrick R. Martone ◽  
Prashant Kaushik
Keyword(s):  
Back Pain ◽  
Young Adult ◽  
Lower Back Pain ◽  
Chronic Lower Back Pain ◽  
Lower Back

scholarly journals OS10.2 Effectiveness and tolerability of lacosamide as add-on therapy in patients with brain tumor-related epilepsy: results from a prospective, non-interventional study in European clinical practice

2019 ◽  
Vol 21 (Supplement_3) ◽  
pp. iii20-iii21
Author(s):  
R Rudà ◽  
S Hellot ◽  
M De Backer ◽  
J Chan ◽  
L Joeres ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Brain Tumor ◽  
Seizure Frequency ◽  
Retention Rate ◽  
Low Grade Glioma ◽  
Low Grade ◽  
Interventional Study ◽  
Who Grade ◽  
Kaplan Meier

Abstract BACKGROUND Data on the use of lacosamide (LCM) for the treatment of brain tumor-related epilepsy (BTRE) are limited. The objective of this study was to evaluate the effectiveness and tolerability of LCM added to 1 or 2 antiepileptic drugs (AEDs) in the treatment of patients with epilepsy due to low-grade primary brain tumor. MATERIAL AND METHODS Prospective, multicenter, single-arm, non-interventional study with a 6-month observation period (EP0045; NCT02276053). LCM was added to existing treatment with 1 or 2 AEDs. Patients aged ≥16 years with BTRE secondary to low-grade glioma (WHO Grade I-II) were eligible. Primary endpoints: patients experiencing a ≥50% reduction in seizure frequency from Baseline to Month 6; Patient’s Global Impression of Change (PGIC) rating at Month 6. Secondary endpoints: Kaplan-Meier estimated retention rate and change from Baseline in quality-of-life to Month 6 (EQ-5D-5L and MDASI-BT). Safety variables: occurrence of adverse drug reactions (ADRs) and ADRs leading to discontinuation. The present analysis was performed for the safety set: all patients who took ≥1 dose of lacosamide. RESULTS The study was conducted between November 2014 and December 2017. Patients were enrolled from 24 sites in Italy, the United Kingdom, the Netherlands, Germany, France, and Spain. 93 patients started LCM (mean [SD] age: 44.5 [14.7] years; 50 [53.8%] male); 14 (15.1%) withdrew from the study by 6 months. 85 (91.4%) patients had low-grade glioma, 3 (3.2%) had suspected glioma, 3 (3.2%) had meningioma, 1 (1.1%) had craniopharyngioma, and 1 (1.1%) had a histologically unverified tumor. At 6-months, 66 (71.0%) patients reported a ≥50% reduction in seizure frequency, 30 (32.3%) of whom were seizure-free. Improvements on PGIC were reported by 49 (52.7%) patients. The Kaplan-Meier estimated 6-month retention rate was 86.0%. Quality of life (EQ-5D-5L) and symptoms outcome measures (MDASI-BT) remained stable. ADRs leading to discontinuation occurred in 4 (4.3%) patients, most commonly vertigo (2 [2.2%] patients). CONCLUSION This is the first prospective, multicenter study focusing on epilepsy due to slow-growing tumors (mainly low-grade gliomas), treated with LCM. The results suggest that LCM reduces seizures in patients with resistant BTRE. The majority of patients noticed a clinical improvement with the addition of LCM. Observed ADRs were consistent with the known safety profile of LCM. STUDY SUPPORTED BY: UCB Pharma.

Panel Approves Duloxetine for Lower Back Pain

2010 ◽  
Vol 38 (9) ◽  
pp. 24
Author(s):  
ELIZABETH MECHCATIE
Keyword(s):  
Back Pain ◽  
Lower Back Pain ◽  
Lower Back

Knowledge of lower back pain by selected demographic variables among clinical students in Abha, Saudi Arabia

2020 ◽  
pp. 1801-1805
Author(s):  
Ibrahim Alburaidi ◽  
Khaled Alravie ◽  
Saleh Qahtani ◽  
Hani Dibssan ◽  
Nawaf Abdulhadi ◽  
...  
Keyword(s):  
Saudi Arabia ◽  
Back Pain ◽  
Lower Back Pain ◽  
Demographic Variables ◽  
Lower Back
Sign in / Sign up

Export Citation Format

Share Document